Back to Search
Start Over
Availability, affordability, and quality of essential anti‐seizure medication in Cambodia
- Source :
- Epilepsia Open, Vol 6, Iss 3, Pp 548-558 (2021), Epilepsia Open, Epilepsia Open, 2021, ⟨10.1002/epi4.12514⟩, Epilepsia Open, The International League Against Epilepsy 2021, ⟨10.1002/epi4.12514⟩
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- International audience; Objective: Epilepsy is a major neurological disorder that requires long-term medical treatment. Once epilepsy is diagnosed, people with epilepsy face many difficulties in accessing treatment (treatment gap). Our objective was to assess the situation regarding the availability, price, affordability, and quality of anti-seizure medication (ASM), which are major determinants of access to treatment. Method: A cross-sectional study was performed in provincial/district hospitals and private pharmacies in urban and rural areas in Cambodia. Data on ASM availability and price were obtained through drug suppliers. Affordability was estimated as the number of day wages the lowest-paid government employee must work to purchase a monthly treatment. Samples of ASM were collected, and the quality of ASM was assessed through Medicine Quality Assessment Reporting Guidelines. Results: Out of 138 outlets visited, only 72 outlets (52.2% [95% CI 43.5-60.7]) had at least one ASM available. Phenobarbital 100 mg was the most available (35.5%), followed by carbamazepine 200 mg (21.7%), phenobarbital 50 mg (11.6%), sodium valproate 500 mg (9.4%), and phenytoin 100 mg (9.4%). In provincial/district hospitals, ASM was provided free of charge. In private pharmacies, affordability for phenobarbital 50 mg and 100 mg was the best, with 0.6 and 0.5 days, respectively, compared to phenytoin 100 mg (1.8 days), and other ASM. No counterfeit ASM was found in this study. Phenytoin sample presented the worst quality (33.0%) compared to carbamazepine (27.8%), and other ASM. Significance: A lack of access to affordable and effective ASM due to low availability and poor quality of ASM was identified. Our research highlights the need for future policy efforts to ensure the quality of ASM and improve their availability. This can be achieved by involving the calculation of their annual needs for these drugs and increasing the national production of ASM.
- Subjects :
- Asia
Seizure medication
media_common.quotation_subject
030231 tropical medicine
Pharmacy
Poor quality
03 medical and health sciences
Epilepsy
0302 clinical medicine
Environmental health
medicine
Humans
Quality (business)
RC346-429
media_common
anti‐seizure medication
treatment gap
Medical treatment
business.industry
anti-seizure medication
Carbamazepine
respiratory system
medicine.disease
musculoskeletal system
3. Good health
respiratory tract diseases
accessibility
Cross-Sectional Studies
Neurology
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Costs and Cost Analysis
Full‐length Original Research
epilepsy
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Neurology (clinical)
Neurology. Diseases of the nervous system
Rural area
Cambodia
Drugs, Essential
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 24709239
- Volume :
- 6
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Epilepsia Open
- Accession number :
- edsair.doi.dedup.....a1d779bf2cbe989d140f6e8102fb50fd
- Full Text :
- https://doi.org/10.1002/epi4.12514⟩